leisure time -WSS

leisure time

author：explore 2025-09-06 04:13:01 - browse：435

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

WSS

Dario to buy mental health app maker Twill in cash and stock deal

NIH study of ME/CFS points to clear biological hallmarks

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Alabama frozen embryo ruling has major implications for IVF clinics

Why you shouldn’t ask, “What country has the best health care?”

PBM reform efforts get punted in Congress

focus

leisure time

focus

Anesthesiologist group: stop taking Ozempic before surgery

Bernie Sanders is gearing up to subpoena pharma CEOs

Peter Hotez and the public health issue of online harassment

New clues to why women have higher risk of autoimmune disorders

Medicare proposal to cover medical devices draws a mixed reaction

PBM reform efforts get punted in Congress

Bright Health sells Medicare Advantage business to Molina

Investment in vaccine development is lagging, report finds

Affirmative action in medical school literally saved lives

Philips to halt sales of sleep apnea machines in U.S.

Wikipedia

NIH study of ME/CFS points to clear biological hallmarks

Philips to halt sales of sleep apnea machines in U.S.

Why Medicare shouldn’t cover every FDA

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Biogen walks away from Aduhelm, years after polarizing approval

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

knowledge

entertainment

focus

hotspot